EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study

Samad Sayed, Rishikesh Kumar, Martin Zarba iD, Md Mahsin, Amina Taleb, Lateefah Alshammari iD, Simon Mairs, Naveen Basappa iD, Michael Kolinsky, Meghan Mahoney, Vishal Navani iD, Tina Cheng und 6 weitere

Current Oncology · 2026

DOI: 10.3390/curroncol33090542 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Current Oncology, 2026. Verfasst von Samad Sayed und 17 weiteren Autor:innen. Beteiligte Einrichtung: Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N5G2, Canada. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Enfortumab vedotin plus pembrolizumab (EVP) is the standard first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC); however, real-world toxicity patterns, timing of onset, and prognostic significance of treatment-related adverse events (AEs) remain incompletely characterized.

Methods

We conducted a retrospective, multicenter analysis of 60 la/mUC patients treated with first-line EVP in Alberta, Canada (September 2024–January 2026). Treatment related toxicities, time to AE onset, dose modifications, and treatment discontinuation were assessed. Progression-free survival (PFS) and overall survival (OS) were analyzed.

Results

The median age was 69 years, 82% of patients were male, and 80% had metastatic disease at treatment initiation. Histology was pure urothelial in 82% and mixed in 18%. Median follow-up was 10.3 months, and the median number of EV and pembrolizumab cycles was seven and eight, respectively. Rash (63%), fatigue (57%), and peripheral neuropathy (47%) were the most common adverse events, with median onset at 17, 29, and 90 days, respectively. Dose reductions occurred in 62%, dose delays in 43%, and treatment discontinuation in 38%. An initial enfortumab vedotin dose of 1.25 mg/kg was associated with improved PFS (HR 0.30, 95% CI 0.13–0.68; p = 0.004) and OS (HR 0.32, 95% CI 0.10–0.97; p = 0.044) compared with 1.0 mg/kg. Neuropathy was associated with improved PFS (HR 0.32, 95% CI 0.14–0.73; p = 0.007) and OS (HR 0.24, 95% CI 0.07–0.87; p = 0.029), while rash was associated with improved OS (HR 0.31, 95% CI 0.11–0.91; p = 0.032).

Conclusions

EVP was associated with frequent treatment-related adverse events requiring dose modifications, and the development of rash and peripheral neuropathy was associated with favorable survival outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

biomarkerdose modificationenfortumab vedotinpembrolizumabreal-world evidencetoxicityurothelial carcinoma

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalenfortumab vedotinpembrolizumab

Autor:innen und Institutionen

  • Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N5G2, Canada.
  • Cross Cancer Institute, University of Alberta, Edmonton, AB T6G1Z2, Canada.
  • Jack Ady Cancer Centre, Alberta Health Services, Lethbridge, AB T1J1W5, Canada.
  • Alberta Health Services, Red Deer, AB T4N4E7, Canada.

ORCID-Profile: Martin Zarba, Lateefah Alshammari, Naveen Basappa, Vishal Navani, Richard Lee-Ying

Zitieren

APA

Sayed, S., Kumar, R., Zarba, M., Mahsin, M., Taleb, A., Alshammari, L., Mairs, S., Basappa, N., Kolinsky, M., Mahoney, M., Navani, V., Cheng, T., Karim, S., Lee-Ying, R., Yip, S., Heng, D. Y. C., North, S., & Alimohamed, N. (2026). Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study. Current Oncology. https://doi.org/10.3390/curroncol33090542

Vancouver

Sayed S, Kumar R, Zarba M, Mahsin M, Taleb A, Alshammari L, et al. Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study. Current Oncology. 2026. doi:10.3390/curroncol33090542

BibTeX
@article{Sayed2026,
  author = {Sayed, Samad and Kumar, Rishikesh and Zarba, Martin and Mahsin, Md and Taleb, Amina and Alshammari, Lateefah and Mairs, Simon and Basappa, Naveen and Kolinsky, Michael and Mahoney, Meghan and Navani, Vishal and Cheng, Tina and Karim, Safiya and Lee-Ying, Richard and Yip, Steven and Heng, Daniel Y C and North, Scott and Alimohamed, Nimira},
  title = {Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study},
  journal = {Current Oncology},
  year = {2026},
  doi = {10.3390/curroncol33090542}
}
Kostenlos starten →